Who
Jason K. Garland
CFO
Company insider
Files Form 4 as: CFO, Repligen; Director, Acutus Medical; EVP, Chief Financial Officer, Integer Holdings.
In numbers
- Trades disclosed
- 70
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $372K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 10 Oct 2018
- Last trade
- 25 Sep 2026
- Last filed
- 28 Sep 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Sep 2026filed 28 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $80K421 at $189.68 | filing |
| 25 Sep 2026filed 28 Sep 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $80K421 at $189.68 | filing |
| 16 Jul 2026filed 17 Jul 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $80K530 at $150.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $80K530 at $150.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $106K733 at $145.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $106K733 at $145.00 | filing |
| 5 Mar 2026filed 23 Mar 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —7,751 at $0.00 | filing |
| 5 Mar 2026filed 23 Mar 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,315 at $0.00 | filing |
| 5 Mar 2026filed 23 Mar 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,315 at $0.00 | filing |
| 5 Mar 2026filed 23 Mar 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —7,751 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $89K715 at $124.97 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $89K715 at $124.97 | filing |
| 27 Feb 2026filed 3 Mar 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $42K327 at $128.73 | filing |
| 27 Feb 2026filed 3 Mar 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $42K327 at $128.73 | filing |
| 25 Sep 2025filed 26 Sep 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $50K412 at $121.68 | filing |
| 3 Mar 2025filed 4 Mar 2025 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,056 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —6,435 at $0.00 | filing |
| 27 Feb 2025filed 28 Feb 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $49K316 at $156.54 | filing |
| 20 Nov 2024filed 21 Nov 2024 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $45K367 at $123.41 | filing |
| 27 Feb 2024filed 29 Feb 2024 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,523 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.